Updated results of a Swedish screening study (GOTEBORG-2), reported in The New England Journal of Medicine by Hugosson et al, indicate that omitting biopsy among individuals with negative magnetic res…
In the phase 1b/2 FELIX study, obecabtagene autoleucel was associated with low incidence of grade 3 or higher immune-related toxicity.
Éliane Gluckman, MD, PhD, FRCP, of Université Paris-Cité and Saint-Louis Hospital, AP-HP, was honored with the ASH Wallace H. Coulter Award for Lifetime Achi…
From FDA approvals to drug discovery, Moffitt led the way this past year
Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative…
Introduction Non-castrating therapies are an unmet clinical need for patients with advanced prostate cancer. To maximize quality of life and prioritize cardiovascular health, we investigated…
Join us to watch leading experts on MPN present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current…
In this issue of Blood, Tilley and colleagues report the discovery of the gene underlying the inherited AnWj-negative phenotype.1 They identified a 6646-ba
The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of hematologic malignancies.
Early Career Award | Cancer Discovery | American Association for Cancer Research .aacrcontent .banner{ width: 100% margin: -20px; } .aacrcontent .banner-sm{ display: none; } .right{float:…
